Peroxisomal Disorders
A heterogeneous group of inherited metabolic disorders marked by absent or dysfunctional PEROXISOMES. Peroxisomal enzymatic abnormalities may be single or multiple. Biosynthetic peroxisomal pathways are compromised, including the ability to synthesize ether lipids and to oxidize long-chain fatty acid precursors. Diseases in this category include ZELLWEGER SYNDROME; INFANTILE REFSUM DISEASE; rhizomelic chondrodysplasia (CHONDRODYSPLASIA PUNCTATA, RHIZOMELIC); hyperpipecolic acidemia; neonatal adrenoleukodystrophy; and ADRENOLEUKODYSTROPHY (X-linked). Neurologic dysfunction is a prominent feature of most peroxisomal disorders.
Subtype terms (7)
More specific conditions that are subtypes of Peroxisomal Disorders in the MeSH hierarchy.
- Acatalasia
- Adrenoleukodystrophy
41 drugs (25 approved, 16 experimental)
- Chondrodysplasia Punctata, Rhizomelic
1 drug experimental
- Mevalonate Kinase Deficiency
1 drug approved
- Refsum Disease
- Refsum Disease, Infantile
6 drugs (5 approved, 1 experimental)
- Zellweger Syndrome
7 drugs (6 approved, 1 experimental)
Drugs by status
Approved for this indication (1)
Phase 3 trials (1)
Phase 2 trials (9)
Other trials (3)
Organizations
Organization Involved with Phase 3 Indications (4)
Organization Involved with Phase 2 Indications (1)